Application of enzymatic hydrolysates of total glycosides of grosvenor momordica fruit to anti-hepatic fibrosis drugs

A technology of total glycoside enzymolysis product and liver fibrosis, which is applied in the field of medical use of Chinese medicinal material extract mogroside enzymolysis product for anti-liver fibrosis, can solve the problems such as no application report of total glycoside enzymolysis product of Mogroside, and achieves The effect of extracts with clear activity, low cost and wide practical value

Inactive Publication Date: 2017-12-19
CHENGDU BIOPURIFY LTD
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

So far, there is no report on the application of total glucosides of Mogrosides in anti-hepatic fibrosis drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of enzymatic hydrolysates of total glycosides of grosvenor momordica fruit to anti-hepatic fibrosis drugs
  • Application of enzymatic hydrolysates of total glycosides of grosvenor momordica fruit to anti-hepatic fibrosis drugs
  • Application of enzymatic hydrolysates of total glycosides of grosvenor momordica fruit to anti-hepatic fibrosis drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1 Mogroside total glycosides hydrolyzate to CCl 4 Effects of induced liver fibrosis in mice

[0034] 1. Materials and Instruments

[0035] ICR mice, female, weighing 18-22 g (provided by Nanjing Qinglongshan Animal Breeding Farm). Wahaha purified water; α-SMA monoclonal antibody (abcam); goat anti-rabbit IgG (bioworld).

[0036] 2. Experimental method

[0037]ICR female mice were divided into blank group, model group, MG-L group (125mg / kg), MG-H group (250 mg / kg), MG-EH-L group (125mg / kg), MG-EH-H group group (250 mg / kg), the drugs were administered by intragastric administration, 20 rats in each group. Mice were injected intraperitoneally with 40% CCl4 (olive oil suspension) 2ml / kg, twice a week to establish a mouse model of liver fibrosis; the blank group was injected intraperitoneally with olive oil 2ml / kg, twice a week. At the same time as the model was established, the drug was given to the stomach for treatment. The mice were killed at the 6th week af...

Embodiment 2

[0046] Example 2 Effect of MG and MG-EH on the expression of α-SMA protein in HSC-T6 induced by TGF-β1

[0047] HSC-T6 is the effector cell of liver fibrosis. Liver fibrosis is the result of the joint action of various cytokines, and the key step is the continuous inflammation to activate HSC and cause a large amount of ECM deposition. Transforming growth factor-β (TGF-β) is a key factor in promoting liver fibrosis, which can activate HSC-T6, and the activated HSC-T6 can release cytokines through autocrine or paracrine, resulting in a large amount of ECM deposition, which eventually causes hepatic fibrosis. fibrosis. In this experiment, the degree of liver fibrosis was judged by detecting the content of α-SMA protein.

[0048] HSC-T6 was purchased from Nanjing Kaiji Biotechnology Development Co., Ltd. HSC-T6 was cultured in DMEM medium containing 10% domestic calf serum in a 37°C, 5% CO2 incubator. The medium was changed every 2 days, and the cells were digested with 0.25% ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention specifically relates to application of the enzymatic hydrolysates of total glycosides of grosvenor momordica fruit to preparation of drugs or/and health products used for preventing or/and treating hepatic fibrosis, belonging to the technical field of prevention and treatment of hepatic fibrosis. The invention discloses novel pharmaceutical application of the enzymatic hydrolysates of total glycosides of grosvenor momordica fruit, i.e., application to the drugs or/and health products used for preventing or/and treating hepatic fibrosis. Experimental materials used in the invention are derived from original plants which are widely available; and the enzymatic hydrolysates are low in cost, definite in extract activity and have good practical value.

Description

technical field [0001] The invention belongs to the field of natural medicines, and in particular relates to a medical application of an enzymatic hydrolyzate of mogroside, an extract of Chinese medicinal materials, for anti-hepatic fibrosis. . Background technique [0002] Hepatic fibrosis (hepatic fibrosis, HF) is a necessary stage for chronic liver disease to develop into cirrhosis, and it is a compensatory response in the process of tissue repair after liver inflammation or injury caused by various pathogenic factors. , ECM) synthesis is greater than degradation resulting in excessive deposition of ECM. Due to the complex pathological mechanism of liver fibrosis, there is still a lack of specific and effective drugs in clinical practice. Clinically, it is necessary to prevent and treat liver fibrosis through multiple links and multiple targets. [0003] Hepatocytes, Kupffer cells, and hepatic sinusoidal endothelial cells in liver tissue can secrete various cytokines s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/42A61K31/7048A61K31/575A61P1/16
CPCA61K31/575A61K31/7048A61K36/42A61K2236/19
Inventor 谢海峰张朝凤胡云岭谢期林罗明锋
Owner CHENGDU BIOPURIFY LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap